ATHE

NASDAQ

Alterity Therapeutics Limited

SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations

News25/Ratings3

Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.

News · 26 weeks44+171%

2025-10-262026-04-19

Mix2890d

SEC Filings14(50%)
Other6(21%)
Insider5(18%)
Leadership3(11%)

Latest news

25 items

1dPR
Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology
- ATH434 reduced functional decline vs placebo at Week 52 on MuSyCA, a newly described MSA composite scale - - Effects seen on both daily function and neurological examination, consistent with previously reported activity on modified UMSARS Part I - - Presentation reinforces ATH434's clinical profile ahead of Phase 3 engagement with regulators - MELBOURNE, Australia and SAN FRANCISCO, April 22, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the presentation of new data analyses from the Phase 2 trial of ATH43
1dSEC
SEC Form 6-K filed by Alterity Therapeutics Limited
6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
2dSEC
SEC Form 6-K filed by Alterity Therapeutics Limited
6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
3dSEC
SEC Form 6-K filed by Alterity Therapeutics Limited
6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
3dSEC
SEC Form 6-K filed by Alterity Therapeutics Limited
6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
6dPR
Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors
MELBOURNE, Australia and SAN FRANCISCO, April 17, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the appointment of Ms Ann Cunningham to its Board of Directors as an independent Non-Executive Director, effective 17th April 2026. Ms Cunningham's appointment further strengthens Alterity's Board composition, adding significant global commercial and strategic expertise as the Company transitions toward late-stage development in Multiple System Atrophy (MSA). Ms Cunningham brings more than 25 years of global pharmac
6dSEC
SEC Form 6-K filed by Alterity Therapeutics Limited
6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
7dPR
Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting
MELBOURNE, Australia and SAN FRANCISCO, April 16, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that Daniel Claassen, M.D., M.S., Professor of Neurology at Vanderbilt University Medical Center and Chief Medical Advisor for Alterity, will deliver an oral presentation during a Late Breaking Session at the American Academy of Neurology (AAN) Annual Meeting taking place April 18-22, 2026 in Chicago, IL, USA. Session: Late-breaking Science 2Type:Oral PresentationTitle:ATH434 Demonstrates Disease-Modifying Signal in
7dSEC
SEC Form 6-K filed by Alterity Therapeutics Limited
6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
8dINSIDER
SEC Form 3 filed by new insider Stamler David Allen
3 - ALTERITY THERAPEUTICS LTD (0001131343) (Issuer)
8dPR
Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy
MELBOURNE, Australia and SAN FRANCISCO, April 15, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it will host a virtual key opinion leader (KOL) event featuring Roy Freeman, MD (Harvard Medical School, Beth Israel Deaconess Medical Center) and Daniel Claassen, MD, MS (Vanderbilt University Medical Center), alongside David Stamler, MD, (CEO, Alterity Therapeutics), to discuss the significant unmet need and current treatment landscape in Multiple System Atrophy (MSA), a rare, rapidly progressive neurodegenera
8dSEC
SEC Form 6-K filed by Alterity Therapeutics Limited
6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
13dINSIDER
SEC Form 3 filed by new insider Gozlan Lawrence Bernard
3 - ALTERITY THERAPEUTICS LTD (0001131343) (Issuer)
13dINSIDER
SEC Form 3 filed by new insider Babarczy Julian Michael
3 - ALTERITY THERAPEUTICS LTD (0001131343) (Issuer)
13dINSIDER
SEC Form 3 filed by new insider Marks Peter Ashley
3 - ALTERITY THERAPEUTICS LTD (0001131343) (Issuer)
14dINSIDER
SEC Form 3 filed by new insider Macnish Niven Abby Sarah
3 - ALTERITY THERAPEUTICS LTD (0001131343) (Issuer)
22dSEC
SEC Form 6-K filed by Alterity Therapeutics Limited
6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
24dPR
Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program
MELBOURNE, Australia and SAN FRANCISCO, March 30, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced it has received positive regulatory feedback following a Type C Meeting with the U.S. Food and Drug Administration (FDA) regarding its planned Phase 3 development program for ATH434 in Multiple System Atrophy (MSA). The Type C Meeting is part of a multidisciplinary strategy to seek alignment with the FDA on readiness to initiate a Phase 3 pivotal trial in MSA. Alterity received written feedback supporting its plans
24dSEC
SEC Form 6-K filed by Alterity Therapeutics Limited
6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
28dSEC
SEC Form 6-K filed by Alterity Therapeutics Limited
6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
35dSEC
SEC Form 6-K filed by Alterity Therapeutics Limited
6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
45dSEC
SEC Form 6-K filed by Alterity Therapeutics Limited
6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
45dPR
Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit
MELBOURNE, Australia and SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity, will participate in the Bell Potter Healthcare Horizons Summit taking place 12-13 March 2026 in Sorrento, Australia. At the conference, Dr. Stamler will participate in a fireside chat entitled, "Optimising Late-stage Clinical Trials to Increase the Odds," and will also host 1-on-1 investor meetings. About Alterity Therapeutics Limited Alterity Therap
50dPR
Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor
MELBOURNE, Australia and SAN FRANCISCO, March 04, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that Daniel O. Claassen, M.D., M.S., was appointed Chief Medical Advisor and will begin his role in March 2026. As a tenured professor, Dr. Claassen will also retain his academic appointment at Vanderbilt University Medical Center. Dr. Claassen is a board-certified neurologist and internationally recognized expert in neurodegenerative diseases, with more than two decades of clinical and translational research in mov
50dSEC
SEC Form 6-K filed by Alterity Therapeutics Limited
6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)